IntelliCell BioSciences

IntelliCell BioSciences develops regenerative medicine that prevents and cures age related diseases.

IntelliCell BioSciences, Inc. operates as a regenerative medicine company. Its proprietary patent pending process involves the application of ultrasonic cavitation (sound waves) to the extracted adipose tissue for the separation of adult autologous vascular cells (AAVC’s) from the blood vessels in adult adipose (fat) tissue. These AAVC’s or stromal vascular fraction are a heterogeneous mixture of regenerative cells and autologous adult stem cells that promote the healing of injured tissue. AAVC’s contain adult stem cells, fibroblasts, growth factors, and other cellular components. The company plans to focus on regenerative medicine in the areas of aesthetics, orthopedics, sports medicine, pain management, and periodontal diseases. IntelliCell BioSciences, Inc. also licenses its technologies in Canada, Australia, New Zealand, Thailand, and the United States. The company is based in New York, New York.